Vial Doses First Patient with Asthma in Phase 1b Study of Vial's IL-13 x TSLP, a Bispecific Antibody Designed for Twice-Yearly Dosing

Vial, a clinical-stage biotechnology company, today announced that it has dosed the first patient in its Phase 1b clinical ...